{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:48:30Z","timestamp":1759366110711,"version":"build-2065373602"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.nrl.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T18:12:40Z","timestamp":1620324760000},"page":"451-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recomendaciones diagn\u00f3stico-terap\u00e9uticas del grupo de trabajo de expertos de FACME ad-hoc sobre el manejo de la trombosis venosa cerebral relacionada con la vacunaci\u00f3n frente a COVID-19"],"prefix":"10.1016","volume":"36","member":"78","reference":[{"key":"10.1016\/j.nrl.2021.05.001_bib0475","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. Geneva; WHO; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/covid19.who.int\/"},{"key":"10.1016\/j.nrl.2021.05.001_bib0480","unstructured":"European Centre for Disease Prevention and Control. COVID-19 situation update for the EU\/EEA, as of 21 April 2021. Solna: ECDC; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/www.ecdc.europa.eu\/en\/cases-2019-ncov-eueea"},{"key":"10.1016\/j.nrl.2021.05.001_bib0485","unstructured":"Ministerio de Ciencia e Innovaci\u00f3n. Sistema de Monitorizaci\u00f3n de la Mortalidad Diaria (MoMo). Exceso de mortalidad. Madrid: MCI; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/momo.isciii.es\/public\/momo\/dashboard\/momo_dashboard.html"},{"key":"10.1016\/j.nrl.2021.05.001_bib0490","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity Trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0495","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0500","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2021.05.001_bib0505","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2021.05.001_bib0510","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - Preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0515","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2021.05.001_bib0520","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2021.05.001_bib0525","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase\u00a0I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nrl.2021.05.001_bib0530","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0535","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0540","unstructured":"Instituto de Salud Carlos III. Red Nacional de Vigilancia Epidemiol\u00f3gica. Informe n.o 74. Situaci\u00f3n de COVID-19 en Espa\u00f1a. Casos diagnosticados a partir 10 de mayo. Informe COVID-19. Madrid: ISCIII; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/INFORMES\/Informes%20COVID-19\/INFORMES%20COVID-19%202021\/Informe%20COVID-19.%20N%C2%BA%2074_14%20de%20abril%20de%202021.pdf"},{"key":"#cr-split#-10.1016\/j.nrl.2021.05.001_bib0545.1","unstructured":"European Medicines Agency. 29 March 2021 update. COVID-19 vaccine safety update. VAXZEVRIA AstraZeneca AB. Amsterdam: EMA"},{"key":"#cr-split#-10.1016\/j.nrl.2021.05.001_bib0545.2","unstructured":"2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf"},{"key":"#cr-split#-10.1016\/j.nrl.2021.05.001_bib0550.1","unstructured":"European Medicines Agency. 14 April 2021 update. COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB. Amsterdam: EMA"},{"key":"#cr-split#-10.1016\/j.nrl.2021.05.001_bib0550.2","unstructured":"2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-april-2021_en.pdf"},{"key":"10.1016\/j.nrl.2021.05.001_bib0555","unstructured":"European Medicines Agency. COVID-19 vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. 20 de abril de 2021. Amsterdam: EMA; 2021 [consultado 30 Abr 2021]. Disponible en: https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood"},{"key":"10.1016\/j.nrl.2021.05.001_bib0560","unstructured":"Federaci\u00f3n de Asociaciones Cient\u00edfico M\u00e9dicas Espa\u00f1olas. COVID-19: Documentos. Madrid: FACME; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/facme.es\/covid-19\/covid-19-documentos\/"},{"key":"10.1016\/j.nrl.2021.05.001_bib0565","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Vacunas COVID-19. Informe de farmacovigilancia. Madrid: AEMPS; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/www.aemps.gob.es\/laAEMPS\/docs\/informe-farmacovigilancia-abril-2021.pdf?x74012"},{"key":"10.1016\/j.nrl.2021.05.001_bib0570","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Vaxzevria (vacuna frente a la COVID-19 de AstraZeneca): actualizaci\u00f3n sobre el riesgo de trombosis. Madrid: AEMPS; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2021-seguridad-1\/vaxzevria-vacuna-frente-a-la-covid-19-de-astrazeneca-actualizacion-sobre-el-riesgo-de-trombosis\/"},{"key":"10.1016\/j.nrl.2021.05.001_bib0575","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0580","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.nrl.2021.05.001_bib0585","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/hum.2007.0051","article-title":"Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia","volume":"18","author":"Hofherr","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nrl.2021.05.001_bib0590","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<360::AID-JGM54>3.0.CO;2-Q","article-title":"Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits","volume":"1","author":"Cichon","year":"1999","journal-title":"J Gene Med"},{"issue":"5 Pt 1","key":"10.1016\/j.nrl.2021.05.001_bib0595","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/mthe.2001.0330","article-title":"Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors","volume":"3","author":"Schnell","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.nrl.2021.05.001_bib0600","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1046\/j.1365-2141.2003.04719.x","article-title":"Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance","volume":"123","author":"Wolins","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0605","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.gt.3302347","article-title":"Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice","volume":"12","author":"Varnavski","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.nrl.2021.05.001_bib0610","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0615","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0620","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccine","author":"Tiede","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.nrl.2021.05.001_bib0625","unstructured":"Brighton Collaboration. Interim case definition of thrombosis with thrombocytopenia syndrome (TTS). Decatur, GA: Brighton Collaboration; 2021 [consultado 22 Abr 2021]. Disponible en: https:\/\/brightoncollaboration.us\/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition\/"},{"key":"10.1016\/j.nrl.2021.05.001_bib0630","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15346","article-title":"Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)","author":"Thaler","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.nrl.2021.05.001_bib0635","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0640","unstructured":"British Society of Haemotology. Guidance from the Expert Haematology Panel (EHP) on Covid-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT). Updated Guidance on Management. Version 1.7. London: BSH; 2021 [consultado 23 Abr 2021]. Disponible en: https:\/\/b-s-h.org.uk\/media\/19590\/guidance-version-17-on-mngmt-of-vitt-20210420.pdf"},{"key":"10.1016\/j.nrl.2021.05.001_bib0645","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000111256","article-title":"Anatomy of cerebral veins and sinuses","volume":"23","author":"Kili\u00e7","year":"2008","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.nrl.2021.05.001_bib0650","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0333102417698707","article-title":"Headache in cerebral venous sinus thrombosis revisited: Exploring the role of vascular congestion and cortical vein thrombosis","volume":"38","author":"Singh","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.nrl.2021.05.001_bib0655","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10194-010-0186-3","article-title":"Headache in cerebral venous thrombosis: Incidence, pattern and location in 200 consecutive patients","volume":"11","author":"Wasay","year":"2010","journal-title":"J Headache Pain"},{"key":"10.1016\/j.nrl.2021.05.001_bib0660","doi-asserted-by":"crossref","first-page":"e20900","DOI":"10.1097\/MD.0000000000020900","article-title":"Presence of red flags in patients with cerebral venous sinus thrombosis admitted to the emergency department because of headache: A STROBE compliant cohort-study","volume":"99","author":"Garc\u00eda-Azor\u00edn","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nrl.2021.05.001_bib0665","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11916-019-0786-9","article-title":"Cerebral venous thrombosis headache","volume":"23","author":"Mehta","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.nrl.2021.05.001_bib0670","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrneurol.2017.104","article-title":"Cerebral venous thrombosis","volume":"13","author":"Silvis","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0675","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3174\/ajnr.A1451","article-title":"Noncontrast CT in deep cerebral venous thrombosis and sinus thrombosis: Comparison of its diagnostic value for both entities","volume":"30","author":"Linn","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0680","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/WNL.0000000000006959","article-title":"Diagnostic accuracy of noncontrast CT imaging markers in cerebral venous thrombosis","volume":"92","author":"Buyck","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2021.05.001_bib0685","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11547-020-01263-2","article-title":"Accuracy of unenhanced CT in the diagnosis of cerebral venous sinus thrombosis","volume":"126","author":"Bonatti","year":"2021","journal-title":"Radiol Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0690","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41598-020-57867-1","article-title":"Diagnostic value of non-contrast brain computed tomography in the evaluation of acute cerebral venous thrombosis","volume":"10","author":"Tayyebi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nrl.2021.05.001_bib0695","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1055\/s-0038-1642636","article-title":"The performance of CT versus MRI in the differential diagnosis of cerebral venous thrombosis","volume":"118","author":"Xu","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.nrl.2021.05.001_bib0700","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2018.05.012","article-title":"Accuracy of magnetic resonance venography in diagnosing cerebral venous sinus thrombosis","volume":"167","author":"Gao","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.nrl.2021.05.001_bib0705","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000478980","article-title":"Venous stasis and cerebrovascular complications in cerebral venous sinus thrombosis","volume":"78","author":"Sato","year":"2017","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0710","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11910-013-0417-5","article-title":"Diagnosis and treatment of cerebral venous and sinus thrombosis","volume":"14","author":"Weimar","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrl.2021.05.001_bib0715","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11910-019-0988-x","article-title":"Cerebral venous thrombosis: An update","volume":"19","author":"Ferro","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrl.2021.05.001_bib0720","first-page":"e217517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","author":"See","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.nrl.2021.05.001_bib0725","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.medcli.2018.11.002","article-title":"Cerebral venous thrombosis following treatment with intravenous immunoglobulin","volume":"153","author":"Sancho Salda\u00f1a","year":"2019","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nrl.2021.05.001_bib0730","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/ijccm.IJCCM_512_17","article-title":"Cerebral venous thrombosis after intravenous immunoglobulin therapy in immune thrombocytopenic purpura","volume":"22","author":"Al-Mendalawi","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.nrl.2021.05.001_bib0735","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrneurol.2017.143","article-title":"Stroke: Patients with CVT urgently need high-quality evidence","volume":"13","author":"Riva","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0740","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1468-1331.2010.03011.x","article-title":"EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients","volume":"17","author":"Einh\u00e4upl","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0745","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.nrl.2021.05.001_bib0750","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/2396987317719364","article-title":"European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - Endorsed by the European Academy of Neurology","volume":"2","author":"Ferro","year":"2017","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.nrl.2021.05.001_bib0755","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0140-6736(91)90607-Q","article-title":"Heparin treatment in sinus venous thrombosis","volume":"338","author":"Einh\u00e4upl","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2021.05.001_bib0760","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000067117","article-title":"Heparin treatment in cerebral sinus and venous thrombosis: Patients at risk of fatal outcome","volume":"15","author":"Mehraein","year":"2003","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.nrl.2021.05.001_bib0765","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/ene.13064","article-title":"Outcome of heparin-treated patients with acute cerebral venous sinus thrombosis: Influence of the temporal pattern of intracerebral haemorrhage","volume":"23","author":"Busch","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0770","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/STROKEAHA.110.588822","article-title":"Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis","volume":"41","author":"Coutinho","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.nrl.2021.05.001_bib0775","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1468-1331.2012.03690.x","article-title":"Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: A randomized controlled trial","volume":"19","author":"Misra","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0780","doi-asserted-by":"crossref","first-page":"357","DOI":"10.17712\/nsj.2015.4.20150375","article-title":"The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis","volume":"20","author":"Afshari","year":"2015","journal-title":"Neurosciences (Riyadh)"},{"key":"10.1016\/j.nrl.2021.05.001_bib0785","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amsu.2017.03.016","article-title":"Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis","volume":"17","author":"Qureshi","year":"2017","journal-title":"Ann Med Surg (Lond)"},{"journal-title":"Stroke","article-title":"Diagnosis and managmenent of cerebral venous sinus thrombosis with vaccine-induced thrombotic thrombocytopenia","year":"2021","key":"10.1016\/j.nrl.2021.05.001_bib0790"},{"key":"10.1016\/j.nrl.2021.05.001_bib0795","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2004.11.006","article-title":"Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia","volume":"116","author":"Matthai","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.nrl.2021.05.001_bib0800","doi-asserted-by":"crossref","DOI":"10.1007\/s11096-021-01260-z","article-title":"Superior outcomes with argatroban for heparin-induced thrombocytopenia: A Bayesian network meta-analysis","author":"Colarossi","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.nrl.2021.05.001_bib0805","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/NRL.0000000000000146","article-title":"Cerebral venous sinus thrombosis due to low-molecular-weight heparin-induced thrombocytopenia","volume":"22","author":"Gleichgerrcht","year":"2017","journal-title":"Neurologist"},{"key":"10.1016\/j.nrl.2021.05.001_bib0810","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/STROKEAHA.111.625574","article-title":"The argatroban and tissue-type plasminogen activator stroke study: Final results of a pilot safety study","volume":"43","author":"Barreto","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.nrl.2021.05.001_bib0815","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/STROKEAHA.117.016720","article-title":"Randomized multicenter trial of ARTSS-2 (argatroban with recombinant tissue plasminogen activator for acute stroke)","volume":"48","author":"Barreto","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.nrl.2021.05.001_bib0820","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.036","article-title":"Safety and feasibility of argatroban. Recombinant tissue plasminogen activator, and intra-arterial therapy in stroke (ARTSS-IA Study)","volume":"27","author":"Berekashvili","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.nrl.2021.05.001_bib0825","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de arganova (argatroban). Madrid: AEMPS; 2021 [consultado 23 Abr 2021]. Disponible en: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/74548\/74548_ft.pdf"},{"key":"10.1016\/j.nrl.2021.05.001_bib0830","first-page":"1","article-title":"Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty","author":"Hwang","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.nrl.2021.05.001_bib0835","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12185-017-2271-8","article-title":"Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: A systematic review and meta-analysis","volume":"106","author":"Sun","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0840","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de bivalirudina. Madrid: AEMPS; 2021 [consultado 23 Abr 2021]. Disponible en: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/80912\/FT_80912.pdf"},{"key":"10.1016\/j.nrl.2021.05.001_bib0855","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de arixtra (fondaparinux s\u00f3dico). Madrid: AEMPS; 2021 [consultado 23 Abr 2021]. Disponible en: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/p\/02206006\/02206006_p.pdf"},{"key":"10.1016\/j.nrl.2021.05.001_bib0845","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.3748\/wjg.14.4576","article-title":"Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis","volume":"14","author":"Thorsteinsson","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0850","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10245330500093492","article-title":"Fondaparinux: A potential new therapy for HIT","volume":"10","author":"Kuo","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.nrl.2021.05.001_bib0860","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clineuro.2018.10.015","article-title":"Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients","volume":"175","author":"Shankar Iyer","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.nrl.2021.05.001_bib0865","first-page":"e4589","article-title":"The role of warfarin and rivaroxaban in the treatment of cerebral venous thrombosis","volume":"11","author":"Fayyaz","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.nrl.2021.05.001_bib0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21556660.2020.1838769","article-title":"Use of oral rivaroxaban in cerebral venous thrombosis","volume":"10","author":"Maqsood","year":"2020","journal-title":"J Drug Assess"},{"key":"10.1016\/j.nrl.2021.05.001_bib0875","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1182\/bloodadvances.2020003244","article-title":"Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)","volume":"4","author":"Connor","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.nrl.2021.05.001_bib0880","first-page":"e13663","article-title":"An observational study to evaluate the effectiveness of rivaroxaban in the management of cerebral venous sinus thrombosis","volume":"13","author":"Fatima","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.nrl.2021.05.001_bib0885","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12883-021-02091-1","article-title":"Rivaroxaban for the treatment of cerebral venous thrombosis","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.nrl.2021.05.001_bib0890","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2018.11.018","article-title":"Apixaban and rivaroxaban in patients with cerebral venous thrombosis","volume":"173","author":"Covut","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.nrl.2021.05.001_bib0895","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jns.2017.09.007","article-title":"Apixaban for the treatment of cerebral venous thrombosis: A case series","volume":"381","author":"Rao","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrl.2021.05.001_bib0900","doi-asserted-by":"crossref","first-page":"597623","DOI":"10.3389\/fneur.2020.597623","article-title":"Comparison of novel oral anticoagulants and vitamin K antagonists in patients with cerebral venous sinus thrombosis on efficacy and safety: A systematic review","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nrl.2021.05.001_bib0905","doi-asserted-by":"crossref","first-page":"e040212","DOI":"10.1136\/bmjopen-2020-040212","article-title":"Direct oral anticoagulants in treatment of cerebral venous thrombosis: A systematic review","volume":"11","author":"Bose","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.nrl.2021.05.001_bib0910","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/rth2.12480","article-title":"Direct oral anticoagulants for unusual-site venous thromboembolism","volume":"5","author":"Riva","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.nrl.2021.05.001_bib0915","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/rth2.12424","article-title":"Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey","volume":"4","author":"Riva","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.nrl.2021.05.001_bib0920","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/STROKEAHA.107.502658","article-title":"Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: A prospective study","volume":"39","author":"Stam","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.nrl.2021.05.001_bib0925","doi-asserted-by":"crossref","first-page":"e005480","DOI":"10.1161\/JAHA.117.005480","article-title":"Epidemiology, endovascular treatment, and prognosis of cerebral venous thrombosis: US center study of 152 patients","volume":"6","author":"Salottolo","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nrl.2021.05.001_bib0930","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1038\/s41598-020-61884-5","article-title":"Endovascular mechanical thrombectomy and on-site chemical thrombolysis for severe cerebral venous sinus thrombosis","volume":"10","author":"Liao","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nrl.2021.05.001_bib0935","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/3-211-27911-3_28","article-title":"Decompressive craniectomy in severe cerebral venous and dural sinus thrombosis","volume":"94","author":"Keller","year":"2005","journal-title":"Acta Neurochir Suppl"},{"key":"10.1016\/j.nrl.2021.05.001_bib0940","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/jcm9030743","article-title":"Cerebral and splanchnic vein thrombosis: Advances, challenges, and unanswered questions","volume":"9","author":"Riva","year":"2020","journal-title":"J Clin Med"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485321000839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485321000839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:12:56Z","timestamp":1759324376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485321000839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0213485321000839"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2021.05.001","relation":{},"ISSN":["0213-4853"],"issn-type":[{"type":"print","value":"0213-4853"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones diagn\u00f3stico-terap\u00e9uticas del grupo de trabajo de expertos de FACME ad-hoc sobre el manejo de la trombosis venosa cerebral relacionada con la vacunaci\u00f3n frente a COVID-19","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}